Shuttle Pharmaceuticals Holdings, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) is a clinical-stage pharmaceutical company that develops novel therapies and diagnostics to improve outcomes for cancer patients treated with radiation therapy. The company focuses on sensitizing cancer cells to radiation, activating DNA damage response pathways, and protecting normal cells; its lead product, Ropidoxuridine (also known as IPdR), is an oral halogenated pyrimidine in Phase II clinical trials for brain tumors and sarcomas; its pre-clinical pipeline includes SP-225, a class IIb HDAC inhibitor modulating immune system regulation; SP-1-303, a selective class I HDAC inhibitor for estrogen receptor-positive breast cancers; and SP-1-161, an HDAC inhibitor targeting the mutated in ataxia-telangiectasia response pathway; additionally, Shuttle advances pretreatment diagnostic blood tests for prostate cancer and theranostic molecules including PSMA-targeted PARP inhibitor conjugates. Founded in 2012 and headquartered in Gaithersburg, Maryland, the company operates primarily in the United States within the biotechnology sector, targeting oncology patients undergoing radiation therapy, surgery, chemotherapy, and immunotherapy. In November 2025, Shuttle completed the acquisition of Molecule.ai, an AI platform for molecular modeling and predictive analytics, in an $8 million cash-and-stock transaction with up to $2 million in contingent milestones, enhancing its drug discovery capabilities and precision radiotherapy solutions.
Daiichi Sankyo (OTCMKTS:DSNKY) & Shuttle Pharmaceuticals (NASDAQ:SHPH) Head to Head Contrast
United Dogecoin Purchases Dogecoin Miners and Secures Renewable Energy Data Centre Site
United Dogecoin Advances Data Centre and Power Infrastructure Strategy to Support DOGE Mining and AI Hosting
Shuttle Pharma Announces Reverse Stock Split will Become Effective on June 11, 2026, at 12:01 a.m., Eastern Time
Shuttle Pharmaceuticals and United Dogecoin Announce Purchase Order for up to 3,000 ElphaPex Dogecoin and Litecoin Mining Rigs
E.F. Hutton & Co. Serves as Exclusive M&A Advisor and Placement Agent on Completed Shuttle Pharmaceuticals–United Dogecoin Merger to Create the Largest Public Dogecoin Miner
United Dogecoin Goes Public in Landmark Merger, Powering a Scaled, Next Generation DOGE Mining Operation
Shuttle Merges with United Dogecoin to Become the World's Largest Public Dogecoin Miner
Short Interest in Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) Drops By 38.6%
Head-To-Head Analysis: Sigyn Therapeutics (OTCMKTS:SIGY) vs. Shuttle Pharmaceuticals (NASDAQ:SHPH)
RETRANSMISSION: Shuttle Pharmaceuticals Launches Autonomous Self Reasoning AI Agent for Scientific Workflows
Shuttle Pharmaceuticals Launches Autonomous Self Reasoning AI Agent for Scientific Workflows
Head-To-Head Review: Shuttle Pharmaceuticals (NASDAQ:SHPH) versus Tempest Therapeutics (NASDAQ:TPST)
E.F. Hutton & Co. Serves as Exclusive Placement Agent on Shuttle Pharmaceuticals' $3.5 Million Public Offering
Shuttle Pharmaceuticals Announces $3.5 Million Public Offering
Utah Approves AI Prescriptions Drugs. How AI Is Saving Time, Cutting Costs - and Why Molecule.ai's Drug Discovery Platform Matters More Than Ever
Shuttle Pharmaceuticals (NASDAQ:SHPH) Trading Down 6.3% – Time to Sell?
Shuttle Pharmaceuticals (NASDAQ:SHPH) Trading Up 16.8% – Still a Buy?
Shuttle Pharmaceuticals Acquires AI Health Platform
Shuttle Pharmaceuticals Announces Above-the-Market $2.5 Million Private Placement at Effective Price per Share of $4.00